24. Clinical outcomes and risk factors for mortality in diabetic patients with staphylococcus aureus pneumonia: A case-control study
Main Article Content
Abstract
The study was conducted to investigate the clinical outcomes and mortality risk factors related to Staphylococcus aureus pneumonia in patients with and without diabetes mellitus (DM). This was a case-control study on 118 patients with S. aureus pneumonia hospitalized between April 2021 and May 2023. The results reveal that diabetic female patients were prone to acquire Staphylococcus aureus pneumonia than non DM group (66.7% vs. 36.6%, p = 0.003); DM patients have more comorbidities (4.64 ± 2.07 vs. 3.46 ± 1.85; p = 0.003) compared to non-DM patients. Clinical outcomes, including 30-day all-cause mortality and pneumonia-related complications, showed no significant difference between patients with and without DM (all p > 0.05). Two independent risk factors for mortality in DM patients with S. aureus pneumonia are age > 65 (OR = 0.09, 95%CI: 0.01-0.64, p = 0.017) and central nervous system disease (OR = 18.54, 95%CI: 1.81-190.07, p = 0.014). The relatively high mortality rate in DM patients, predominantly attributed to MRSA infection, underscores the importance of staying focus on the diagnosis and adopting an appropriate initial antibiotic treatment approach. It is crucial to particularly note individuals with multiple comorbidities, especially those with central nervous system diseases.
Article Details
Keywords
Staphylococcus aureus, pneumonia, diabetic mellitus, mortality
References
2. Lee LN, Chou WR, Wang JY, et al. Characteristics and local risk factors of community-acquired and health-care-associated Staphylococcus aureus pneumonia. Sci Rep. 2022; 12(1): 18670. doi:10.1038/s41598-022-23246-1.
3. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 2005; 128(3): 1414-1422. doi:10.1378/chest.128.3.1414
4. International Diabetes Federation. IDF Diabetes Atlas 11th Edition. Brussels, Belgium. 2021.
5. Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol. 2015; 83(5): 401-408. doi:10.5603/PiAP.2015.0065.
6. Zhang QR, Chen H, Liu B, Zhou M. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics: a single-center, retrospective analysis. Chin Med J (Engl). 2019; 132(12): 1429-1434. doi:10.1097/CM9.0000000000000270.
7. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44(Suppl 1): S15-S33. doi/10.2337/dc21-S002.
8. Anantha RV, Jegatheswaran J, Pepe DL, Priestap F, Delport J, Haeryfar SM, McCormick JK, Mele T. Risk factors for mortality among patients with Staphylococcus aureus bacteremia: a single-centre retrospective cohort study. CMAJ Open. 2014 Oct 1; 2(4): E352-9. doi: 10.9778/cmajo.20140018.
9. Thabet N, Shindo Y, Okumura J, et al. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci. 2022; 84(2): 247-259. doi:10.18999/nagjms.84.2.247.
10. Hindy JR, Quintero-Martinez JA, Lahr BD, DeSimone DC, Baddour LM. Staphylococcus aureus bacteraemia and mortality: a population-based study in Olmsted County, Minnesota, from 2006 to 2020. Infect Dis (Lond). 2023 Jan;55(1):1-8. doi: 10.1080/23744235.2022.2123561.
11. van der Vaart TW, Prins JM, Soetekouw R, van Twillert G, Veenstra J, Herpers BL, Rozemeijer W, Jansen RR, Bonten MJM, van der Meer JTM. All-Cause and Infection-Related Mortality in Staphylococcus aureus Bacteremia, a Multicenter Prospective Cohort Study. Open Forum Infect Dis. 2022 Nov 30; 9(12): ofac653. doi: 10.1093/ofid/ofac653.
12. Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, Fakhran SS, Chappell JD, Casimir G, Courtney DM, Trabue C, Waterer GW, Bramley A, Magill S, Jain S, Edwards KM, Grijalva CG. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. 2016 Aug 1; 63(3): 300-9. doi: 10.1093/cid/ciw300.
13. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis. 2013; 13: 268. doi:10.1186/1471-2334-13-268.
14. Di Yacovo S, Garcia-Vidal C, Viasus D, et al. Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus. Medicine (Baltimore). 2013; 92(1): 42-50. doi:10.1097/MD.0b013e31827f602a.
15. Barmanray RD, Cheuk N, Fourlanos S, Greenberg PB, Colman PG, Worth LJ. In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19. BMJ Open Diabetes Res Care. 2022; 10(4): e002880. doi:10.1136/bmjdrc-2022-002880.
16. Huang D, He D, Gong L, et al. Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus. Crit Care. 2021; 25(1): 419. doi:10.1186/s13054-021-03841-w.